Applied Genetic Technologies (NASDAQ:AGTC) Upgraded to Hold by Zacks Investment Research

Zacks Investment Research upgraded shares of Applied Genetic Technologies (NASDAQ:AGTC) from a sell rating to a hold rating in a research note released on Friday, March 30th.

According to Zacks, “Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. “

How to Become a New Pot Stock Millionaire

Several other equities research analysts also recently weighed in on AGTC. ValuEngine downgraded Applied Genetic Technologies from a sell rating to a strong sell rating in a report on Sunday, December 31st. Cantor Fitzgerald reiterated a hold rating and issued a $9.00 price objective on shares of Applied Genetic Technologies in a research report on Wednesday, January 17th. HC Wainwright set a $8.00 price objective on Applied Genetic Technologies and gave the stock a buy rating in a research report on Friday, February 9th. Finally, Wedbush reiterated an outperform rating on shares of Applied Genetic Technologies in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $9.00.

Shares of AGTC opened at $4.90 on Friday. The company has a market capitalization of $91.43, a P/E ratio of 245.00 and a beta of 2.10. Applied Genetic Technologies has a 52-week low of $3.25 and a 52-week high of $6.45.

Applied Genetic Technologies (NASDAQ:AGTC) last posted its quarterly earnings data on Friday, February 9th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.20). Applied Genetic Technologies had a negative net margin of 33.24% and a negative return on equity of 9.21%. The firm had revenue of $4.85 million during the quarter, compared to analyst estimates of $8.72 million. During the same period in the previous year, the company posted $0.10 earnings per share. Applied Genetic Technologies’s revenue was down 55.5% compared to the same quarter last year. equities analysts anticipate that Applied Genetic Technologies will post -1.3 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in AGTC. Citadel Advisors LLC increased its position in Applied Genetic Technologies by 304.6% during the 3rd quarter. Citadel Advisors LLC now owns 41,270 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 31,070 shares in the last quarter. Two Sigma Investments LP increased its position in Applied Genetic Technologies by 29.9% during the 4th quarter. Two Sigma Investments LP now owns 60,892 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 14,011 shares in the last quarter. Spark Investment Management LLC increased its position in Applied Genetic Technologies by 122.1% during the 4th quarter. Spark Investment Management LLC now owns 107,700 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 59,200 shares in the last quarter. 683 Capital Management LLC purchased a new stake in Applied Genetic Technologies during the 4th quarter worth about $778,000. Finally, Municipal Employees Retirement System of Michigan increased its position in Applied Genetic Technologies by 66.7% during the 4th quarter. Municipal Employees Retirement System of Michigan now owns 311,820 shares of the biotechnology company’s stock worth $1,123,000 after purchasing an additional 124,810 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2018/04/17/applied-genetic-technologies-agtc-lifted-to-hold-at-zacks-investment-research.html.

About Applied Genetic Technologies

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.

Get a free copy of the Zacks research report on Applied Genetic Technologies (AGTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply